Weekly doses of semaglutide, a GLP-1 receptor originally developed to treat diabetes, could help approximately 93 million U.S. adults lose weight and reduce their risk of adverse cardiovascular events, according to new research published in Cardiovascular Drugs and Therapy. Novo Nordisk sells and markets subcutaneous treatments of semaglutide 2.4 mg under the brand name Wegovy.

The FDA made a special announcement about its decision, describing the news as "a major advance for public health."

A majority of U.S. cardiologists would accept a cut in pay to achieve a significantly better work-life balance.

According to the same report, 43% of cardiologists with children said they feel conflicted about not spending enough time at home.

Nanoflex Robotics, a healthcare technology startup based out of Switzerland, has installed its remote-ready robotics system for neurovascular procedures in the United States for the first time

The new-look robotics system can help specialists perform remote mechanical thrombectomies from bedside or as far as thousands of miles away. 

Patients who take diuretics, renin-angiotensin system (RAD) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) at the same time face a much higher risk of developing acute kidney injury (AKI)

“Aspirin is no longer a one-size-fits-all preventive tool for older adults," according to one specialist with Michigan Medicine. 

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."